NeuroSense Secures South Korean Patent for ALS Drug PrimeC, Bolstering Global IP Ahead of Phase 3

summarizeSummary

NeuroSense Therapeutics announced it has been granted a South Korean patent for PrimeC, its lead drug candidate for ALS, strengthening its global intellectual property portfolio as it prepares for Phase 3 development.

check_boxKey Events · Product Development and Regulatory · NRSN

• South Korean Patent Granted for PrimeC

  The Korean Intellectual Property Office (KIPO) has issued a patent covering the composition of PrimeC, NeuroSense's lead drug candidate for Amyotrophic Lateral Sclerosis (ALS).

• Broad IP Protection

  The patent claims cover PrimeC's proprietary tablet formulation, manufacturing process, pharmacokinetic characteristics, and pharmaceutical use for the treatment of ALS, providing protection through 2042.

• Strengthens Global Portfolio

  This grant expands NeuroSense's intellectual property protection in a significant pharmaceutical market, following recent patent advancements in Japan, Brazil, Australia, and the United States.

• Supports Phase 3 Development

  The expanded IP portfolio further strengthens the company's position as it prepares to initiate its pivotal Phase 3 PARAGON study for PrimeC in ALS.

auto_awesomeAnalysis · NRSN · Life Sciences

This patent grant in South Korea is important for NeuroSense as it expands intellectual property protection for PrimeC, their lead ALS drug candidate, in a key pharmaceutical market. Securing patents globally is crucial for a biotechnology company, especially one preparing for pivotal Phase 3 trials. This positive development helps strengthen the company's long-term commercialization strategy and provides a boost to sentiment, particularly given the company's recent 'going concern' warning and Nasdaq compliance issues.